Compare Stocks: BDRX, PHIO, ANEB, and BLRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$0.32 +6.7%	$0.35	$0.00 ▼ $2.90	$13.05M	-1.82	33,746 shs	1,079 shs
BDRX Biodexa Pharmaceuticals	$1.52 -2.6%	$2.30	$1.02 ▼ $59.40	$1.61M	1.23	270,487 shs	10,391 shs
BLRX BioLineRx	$2.79 +2.5%	$3.01	$2.15 ▼ $4.56	$11.88M	1.54	8,882 shs	3,075 shs
PHIO Phio Pharmaceuticals	$1.09	$1.04	$0.81 ▼ $4.19	$12.66M	0.82	191,614 shs	93,621 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	-9.09%	-10.82%	-34.78%	-87.50%
BDRX Biodexa Pharmaceuticals	+4.00%	+6.12%	-31.28%	-52.73%	-95.48%
BLRX BioLineRx	+3.01%	-0.14%	-9.15%	-7.01%	-29.67%
PHIO Phio Pharmaceuticals	+0.93%	+2.83%	+5.83%	+1.87%	-50.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$0.32 +6.7%	$0.35	$0.00 ▼ $2.90	$13.05M	-1.82	33,746 shs	1,079 shs
BDRX Biodexa Pharmaceuticals	$1.52 -2.6%	$2.30	$1.02 ▼ $59.40	$1.61M	1.23	270,487 shs	10,391 shs
BLRX BioLineRx	$2.79 +2.5%	$3.01	$2.15 ▼ $4.56	$11.88M	1.54	8,882 shs	3,075 shs
PHIO Phio Pharmaceuticals	$1.09	$1.04	$0.81 ▼ $4.19	$12.66M	0.82	191,614 shs	93,621 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	-9.09%	-10.82%	-34.78%	-87.50%
BDRX Biodexa Pharmaceuticals	+4.00%	+6.12%	-31.28%	-52.73%	-95.48%
BLRX BioLineRx	+3.01%	-0.14%	-9.15%	-7.01%	-29.67%
PHIO Phio Pharmaceuticals	+0.93%	+2.83%	+5.83%	+1.87%	-50.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	1.00	Sell	N/A	N/A
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
BLRX BioLineRx	1.00	Sell	N/A	N/A
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,184.40% Upside

Current Analyst Ratings Breakdown

Latest BDRX, PHIO, ANEB, and BLRX Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/3/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.28 per share	N/A
BDRX Biodexa Pharmaceuticals	$470K	3.33	N/A	N/A	$110.30 per share	0.01
BLRX BioLineRx	$1.18M	10.33	N/A	N/A	$5.36 per share	0.52
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.48M	-$0.19	N/A	N/A	N/A	N/A	-74.57%	-68.96%	9/23/2026 (Estimated)
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/11/2026 (Estimated)
BLRX BioLineRx	-$1.17M	-$1.92	N/A	N/A	N/A	-563.70%	-37.73%	-19.42%	N/A
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-87.41%	-79.76%	N/A

Latest BDRX, PHIO, ANEB, and BLRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A
5/27/2026	Q1 2026	BLRX BioLineRx	-$1.04	-$0.36	+$0.68	N/A	$0.34 million	$0.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	6.24	6.24
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
BLRX BioLineRx	0.16	1.58	1.43
PHIO Phio Pharmaceuticals	N/A	8.39	8.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BDRX Biodexa Pharmaceuticals	17.51%
BLRX BioLineRx	1.56%
PHIO Phio Pharmaceuticals	57.31%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BDRX Biodexa Pharmaceuticals	0.34%
BLRX BioLineRx	1.10%
PHIO Phio Pharmaceuticals	0.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	40.79 million	7.91 million	Not Optionable
BDRX Biodexa Pharmaceuticals	20	1.03 million	1.03 million	Not Optionable
BLRX BioLineRx	40	4.37 million	4.32 million	Optionable
PHIO Phio Pharmaceuticals	10	11.62 million	11.51 million	Not Optionable

BDRX, PHIO, ANEB, and BLRX Headlines

Recent News About These Companies

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein

August 13 at 8:16 PM | jsonline.comJ

Q3 EPS Estimates for Phio Pharmaceuticals Lowered by Sidoti

August 13 at 1:43 AM | americanbankingnews.com

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

August 12 at 3:11 AM | finanznachrichten.de

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

August 12 at 3:11 AM | finance.yahoo.com

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 6, 2026 | newsfilecorp.comN

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

July 21, 2026 | newsfilecorp.comN

Phio Pharmaceuticals expands global patent portfolio with new international patent milestones

July 15, 2026 | msn.com

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

July 15, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

June 26, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

June 25, 2026 | finance.yahoo.com

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

June 24, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

June 18, 2026 | finance.yahoo.com

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

May 27, 2026 | tennessean.comT

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 8, 2026 | finanznachrichten.de

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...

April 14, 2026 | finanznachrichten.de

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

April 13, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

April 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, PHIO, ANEB, and BLRX Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.32 +0.02 (+6.67%)

As of 03:35 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.52 -0.04 (-2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$1.51 -0.01 (-0.92%)

As of 07:41 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

BioLineRx NASDAQ:BLRX

$2.79 +0.07 (+2.50%)

Closing price 03:59 PM Eastern

Extended Trading

$2.76 -0.02 (-0.82%)

As of 07:34 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Phio Pharmaceuticals NASDAQ:PHIO

$1.09 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 -0.01 (-0.46%)

As of 06:37 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, PHIO, ANEB, and BLRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, PHIO, ANEB, and BLRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, PHIO, ANEB, and BLRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, PHIO, ANEB, and BLRX Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

Biodexa Pharmaceuticals NASDAQ:BDRX

BioLineRx NASDAQ:BLRX

Phio Pharmaceuticals NASDAQ:PHIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, PHIO, ANEB, and BLRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, PHIO, ANEB, and BLRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, PHIO, ANEB, and BLRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, PHIO, ANEB, and BLRX Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

Biodexa Pharmaceuticals NASDAQ:BDRX

BioLineRx NASDAQ:BLRX

Phio Pharmaceuticals NASDAQ:PHIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools